Wall Street analysts expect Globus Medical (GMED) to post quarterly earnings of $0.55 per share in its upcoming report, which indicates a year-over-year increase of 3.8%. Revenues are expected to be $586.66 million, up 112% from the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Before a company announces its earnings, it is essential to ...

Investors with an interest in Medical - Instruments stocks have likely encountered both Globus Medical (GMED) and Penumbra (PEN) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Sc ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores a ...

Globus Medical (GMED) continues to gain from surging demand for its Musculoskeletal Solutions products. Meanwhile, the company is expanding in the overseas markets through the expansion of direct and distributor sales force. Yet, we are worried about a challenging macroeconomic scenario that continues to plague Globus Medical’s profit margins. It has a Zacks Rank #3 (Hold) at present.GMED is gaining market share in the musculoskeletal solutions space, banking on the strong performance of its implantable dev ...

Globus Medical, Inc. (NYSE:GMED) Q4 2023 Earnings Conference Call February 20, 2024 4:30 PM ET Company Participants Brian Kearns - Senior Vice President, Business Development and Investor Relations Daniel Scavilla - President and Chief Executive Officer Keith Pfeil - Chief Operating Officer and Chief Financial Officer Conference Call Participants Vikramjeet Chopra - Wells Fargo Securities Steven Lichtman - Oppenheimer Matt Blackman - Stifel Shagun Singh - RBC Capital Markets David Saxon - Needham & Company ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to _______________ Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in its charter) DELAWARE 04-3744954 (State or other ju ...

Globus Medical, Inc. (NYSE:GMED) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Brian Kearns - SVP, Business Development & IR Daniel Scavilla - President, CEO & Director Keith Pfeil - SVP & CFO Conference Call Participants Matthew Miksic - Barclays Bank Shagun Chadha - RBC Capital Markets Vikramjeet Chopra - Wells Fargo Securities Andrew Ranieri - Morgan Stanley Jason Wittes - ROTH MKM Partners Ryan Zimmerman - BTIG Samuel Brodovsky - Truist Securities Matthew O’Brien - Pi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to _______________ Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in its charter) DELAWARE 04-3744954 (State or ...

Globus Medical, Inc. (NYSE:GMED) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Brian Kearns - Senior Vice President-Business Development & Investor Relations Dan Scavilla - President & Chief Executive Officer Keith Pfeil - Senior Vice President & Chief Financial Officer Conference Call Participants Matt Miksic - Barclays Caitlin Cronin - Canaccord Genuity Lin Zhang - Truist Securities Operator Welcome to Globus Medical's Second Quarter 2023 Earnings Call. At this time, all ...

OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to _______________ Commission File No. 001-35621 GLOBUS MEDICAL, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) (Exact name of registrant as specified in its charter) (State or other jurisdiction of in ...